我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

卡维地洛与美托洛尔治疗缺血性心脏病心力衰竭的疗效观察(PDF)

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2005年第6期
页码:
592-594
栏目:
临床研究
出版日期:
2005-12-05

文章信息/Info

Title:
Therapeutic effect of carvedilol and metoprolol on ischemic heart disease combined with congestive heart failure
作者:
左梅;  吴栋梁;  陈平;  李阳
中铁20局中心医院心内科, 陕西 咸阳 712000
Author(s):
ZUO Mei ; WU Dongliang; CHEN Ping; LI Yang
Department of Cardiology,Central Hospital of China Railway 20th Bureau, Xianyang, Shaanxi 712000,China
关键词:
心脏病;  缺血性; 心力衰竭; 充血性; 卡维地洛 ; 美托洛尔
Keywords:
ischemic heart disease; heart failure congestive; carvedilol; metoprolol
分类号:
R541.4;R541.6
DOI:
-
文献标识码:
A
摘要:
目的 观察卡维地洛和美托洛尔对缺血性心脏病心力衰竭患者的临床疗效。方法 缺血性心脏病心力衰竭患者80例，左室射血分数（LVEF）≤0.45，心功能（NYHA）Ⅱ~Ⅳ级，常规治疗基础上随机分为卡维地洛组和美托洛尔组，治疗3月后，观察两种药物对心功能及运动耐量的影响。应用心脏彩色超声仪测定心功能基线值及3月后的变化。用6 min步行距离测定运动耐量的改善程度。结果 经过3月的治疗，卡维地洛组与美托洛尔组心率、血压、运动耐量改善程度及心功能均有明显改善，且卡维地洛组6 min步行试验结果，收缩压、舒张压变化及左室收缩末容积（LVESV）、左室舒张末容积（LVEDV）、LVEF改善程度明显优于美托洛尔组（P<0.01)。结论 在常规治疗基础上卡维地洛、美托洛尔对缺血性心脏病的治疗均有显著效果，前者在改善运动耐量、LVEDV、 LVESV及心室射血方面更优。
Abstract:
AIM To investigate the therapeutic effects of carvedilol and metoprolol, the β- receptor inhibitors, on cardiac function and activity tolerance in patients with ischemic heart disease and congestive heart failure (CHF). METHODS Eighty patients of the ischemic heart disease with CHF (LVEF ≤45%, NYHA of grade II to IV), who received the routine treatment at the same time, were randomly divided into carvedilol and metoprolol groups and treated respectively for three months. The changes of the heart function were observed by color Doppler and the activity tolerance was determined by 6 min walking test. RESULTS At the end of the three-month treatment, activity tolerance and the heart function of the carvedivol and metoprolol groups were remarkably improved. The left ventricular end systolic volume (LVESV), the left ventricular end diastolic volume (LVEDV )and the LVEF of the Carvedilol group were higher than those of the metoprolol groups(P<0.01). CONCLUSION Carvedilol and metoprolol are very effective in the treatment of the heart disease with CHF and carredilol is better than metoprolol in the improvement of activity tolerance, the LVESV, the LVEDV and the LVEF.

参考文献/References

［1］ Ho KK, Anderson KM, Kannel WB. Survial after the onset of congestive heart failure in framingham heart study subjects［J］. Circulation, 1993,88:107-115.

［2］ 戴闺柱. 心力衰竭生物学治疗的新认识［J］. 中华心血管病杂志,2000,28:470-472.

［3］ 中华医学会心血管病学分会，中华心血管病杂志编委会. 慢性收缩性心力衰竭治疗建议［J］. 中华心血管病杂志,2002,30:7-23.

［4］ MERITHF Study Group.Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF)［J］. Lancet,1999,353:2001-2007.

［5］ CIBISⅡ Investigator and Committees. The cardiac insufficiency bisoprolol Study Ⅱ (CIBISⅡ): a randomized trial［J］. Lancet,1999,353:9-13.

［6］ Packer M,Bristow MR,Cohn JN, et al. The effect of carvedilol on survival in patients with chronic heart failure［J］. N Engl J Med,1996,334:1349-1355.

［7］ Packer M,Colucci WS, Sackner-Bernstein JD,et al. Doubleblind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure.The PRECISE Trial［J］. Circulation,1996,94:2793-2798.

［8］ Garluch CD, Zhang H, Mussge A, et al. Betablockers reduce the release and synthesis of endothelin1 inhuman endothelial cell［J］. Eur J Clin invest,1999,29(1):12-16.

［9］ Cucchini F. Chronic treatment of dilated cardiomyopathy by beta blocking agents. Clinical and hemodynamic followup［J］. G Ital Cardiol,1988, 18:835-842.

［10］Feuerstein GZ, Bril A ,Ruffolo RR, et al. Protective effects of carvedilol in the myocardium ［J］. Am J Cardiol,1997,80(11)：L41-L42.

备注/Memo

备注/Memo:
收稿日期：2005-05-20.作者简介：左梅，主治医师，硕士Tel:(0910)3785472 Email:zuoyimei123@yahoo.com.cn
更新日期/Last Update: 2010-01-06